FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

György Sölétormos

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Co-author Network

Publications

TOP 3
György Sölétormos; Catharine M Sturgeon; Bengt Tholander; Malgorzata K Tuxen; Vivian Barak; Patrick M Bossuyt; Eleftherios P Diamandis; Michael J Duffy; Massimo Gion; Daniel F Hayes; Per Hyltoft Petersen; Rolf M Lamerz; Dorte Lisbet Nielsen; Paul Sibley; Johannes M G Bonfrer
Design of tumor biomarker-monitoring trials: a proposal by the European Group on Tumor Markers.
Thore Hillig; Flemming Lund; Henrik Mygind; Carsten Pedersen; Marie F Breinholt; Maria-Benedicte Franzmann; György Sölétormos; Jørgen Thode; Martin Rudnicki
Assessing HER2 amplification by IHC, FISH, and real-time polymerase chain reaction analysis (real-time PCR) following LCM in formalin-fixed paraffin embedded tissue from 40 women with ovarian cancer.
Charlotte Barfod; Peter Anthony Berlac; Jakob Klim Danker; Marlene Mauson Pankoke Lauritzen; Freddy K Lippert; Lars Hyldborg Lundstrøm; György Sölétormos; Kristian Antonsen; Kai Henrik Wiborg Lange
The formation and design of the 'Acute Admission Database'- a database including a prospective, observational cohort of 6279 patients triaged in the emergency department in a larger Danish hospital.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of György Sölétormos (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: György Sölétormos; Catharine M Sturgeon; Bengt Tholander; Malgorzata K Tuxen; Vivian Barak; Patrick M Bossuyt; Eleftherios P Diamandis; Michael J Duffy; Massimo Gion; Daniel F Hayes; Per Hyltoft Petersen; Rolf M Lamerz; Dorte Lisbet Nielsen; Paul Sibley; Johannes M G Bonfrer
Design of tumor biomarker-monitoring trials: a proposal by the European Group on Tumor Markers.
Clinical chemistry 2013;59(1):52-9.
2012: Thore Hillig; Flemming Lund; Henrik Mygind; Carsten Pedersen; Marie F Breinholt; Maria-Benedicte Franzmann; György Sölétormos; Jørgen Thode; Martin Rudnicki
Assessing HER2 amplification by IHC, FISH, and real-time polymerase chain reaction analysis (real-time PCR) following LCM in formalin-fixed paraffin embedded tissue from 40 women with ovarian cancer.
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2012;120(12):1000-7.
2012: Charlotte Barfod; Peter Anthony Berlac; Jakob Klim Danker; Marlene Mauson Pankoke Lauritzen; Freddy K Lippert; Lars Hyldborg Lundstrøm; György Sölétormos; Kristian Antonsen; Kai Henrik Wiborg Lange
The formation and design of the 'Acute Admission Database'- a database including a prospective, observational cohort of 6279 patients triaged in the emergency department in a larger Danish hospital.
Scandinavian journal of trauma, resuscitation and emergency medicine 2012;20():29.
2012: Charlotte Barfod; Peter Anthony Berlac; Jakob Klim Danker; Jakob Lundager Forberg; Marlene Mauson Pankoke Lauritzen; Freddy K Lippert; Lars Hyldborg Lundstrøm; György Sölétormos; Kristian Antonsen; Kai Henrik Wiborg Lange
Abnormal vital signs are strong predictors for intensive care unit admission and in-hospital mortality in adults triaged in the emergency department - a prospective cohort study.
Scandinavian journal of trauma, resuscitation and emergency medicine 2012;20():28.
2011: Per Hyltoft Petersen; György Sölétormos; Merete Frejstrup Pedersen; Flemming Lund
Interpretation of increments in serial tumour biomarker concentrations depends on the distance of the baseline concentration from the cut-off.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2011;49(2):303-10.
2010: Bahir Aldulaymi; Ib J Christensen; György Sölétormos; Per Jess; Svend Erik Nielsen; Søren Laurberg; Nils Brünner; Hans J Nielsen
Chemoradiation-induced changes in serum CEA and plasma TIMP-1 in patients with locally advanced rectal cancer.
Anticancer research 2010;30(11):4755-9.
2010: Bahir Aldulaymi; Ib J Christensen; György Sölétormos; Per Jess; Svend Erik Nielsen; Nils Brünner; Hans J Nielsen
Changes in soluble CEA and TIMP-1 levels during adjuvant chemotherapy for stage III colon cancer.
Anticancer research 2010;30(1):233-7.
2008: Catharine M Sturgeon; Michael J Duffy; Ulf-Hakan Stenman; Hans Lilja; Nils Brünner; Daniel W Chan; Richard Babaian; Robert C Bast; Barry Dowell; Francisco J Esteva; Caj Haglund; Nadia Harbeck; Daniel F Hayes; Mads Holten-Andersen; George G Klee; Rolf Lamerz; Leendert H Looijenga; Rafael Molina; Hans Jørgen Nielsen; Harry Rittenhouse; Axel Semjonow; Ie-Ming Shih; Paul Sibley; György Sölétormos; Carsten Stephan; Lori J Sokoll; Barry R Hoffman; Eleftherios P Diamandis
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
Clinical chemistry 2008;54(12):e11-79.
2008: Per Hyltoft Petersen; Sverre Sandberg; Natàlia Iglesias; György Sölétormos; Aasne Karine Aarsand; Ivan Brandslund; Lone G M Jørgensen
'Likelihood-ratio' and 'odds' applied to monitoring of patients as a supplement to 'reference change value' (RCV).
Clinical chemistry and laboratory medicine : CCLM / FESCC 2008;46(2):157-64.
2005: Rafael Molina; Vivian Barak; Arie Van Dalen; Michael J Duffy; Roland Einarsson; Massimo Gion; Helenka Goike; Rolf Lamerz; Marius Nap; György Sölétormos; Petra Stieber
Tumor markers in breast cancer- European Group on Tumor Markers recommendations.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2005;26(6):281-93.
2005: György Sölétormos; Axel Semjonow; Paul E C Sibley; Rolf Lamerz; Per Hyltoft Petersen; Walter Albrecht; Peter Bialk; Massimo Gion; Frank Junker; Hans-Peter Schmid; Hein Van Poppel
Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice.
Clinical chemistry 2005;51(8):1342-51.
2004: György Sölétormos; D Nielsen; V Schiøler; Henning Mouridsen; Per Dombernowsky
Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPA.
European journal of cancer (Oxford, England : 1990) 2004;40(4):481-6.
2002: MK Tuxen; György Sölétormos; Per Dombernowsky
Serum tumor marker CA 125 for monitoring ovarian cancer during follow-up.
Scandinavian journal of clinical and laboratory investigation 2002;62(3):177-88.
2001: György Sölétormos
Serological tumor markers for monitoring breast cancer.
Danish medical bulletin 2001;48(4):229-55.
2001: György Sölétormos; Per Hyltoft Petersen; D Nielsen
Computer-simulated tumor-marker data used to compare progression criteria for cytokeratin tissue polypeptide antigen in metastatic breast cancer.
Clinical chemistry 2001;47(11):2035-7.
2001: MK Tuxen; György Sölétormos; Per Hyltoft Petersen; Per Dombernowsky
Interpretation of sequential measurements of cancer antigen 125 (CA 125), carcinoembryonic antigen (CEA), and tissue polypeptide antigen (TPA) based on analytical imprecision and biological variation in the monitoring of ovarian cancer.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2001;39(6):531-8.
2001: MK Tuxen; György Sölétormos; Per Dombernowsky
Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy.
British journal of cancer 2001;84(10):1301-7.
2001: György Sölétormos; F Bach
Cerebrospinal fluid cytokeratins for diagnosis of patients with central nervous system metastases from breast cancer.
Clinical chemistry 2001;47(5):948-50.
2001: György Sölétormos; F Bach
Tissue polypeptide-specific antigen (TPS) concentrations in cerebrospinal fluid in patients with breast cancer metastases in the central nervous system.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2001;39(2):170-2.
2000: MK Tuxen; György Sölétormos; Gordon J S Rustin; Ann Nelstrop; Per Dombernowsky
Biological variation and analytical imprecision of CA 125 in patients with ovarian cancer.
Scandinavian journal of clinical and laboratory investigation 2000;60(8):713-21.
2000: György Sölétormos; V Schiøler
Description of a computer program to assess cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen information during monitoring of metastatic breast cancer.
Clinical chemistry 2000;46(8 Pt 1):1106-13.
2000: György Sölétormos; P Hyltoft Petersen; Per Dombernowsky
Progression criteria for cancer antigen 15.3 and carcinoembryonic antigen in metastatic breast cancer compared by computer simulation of marker data.
Clinical chemistry 2000;46(7):939-49.
2000: György Sölétormos; Per Hyltoft Petersen; Per Dombernowsky
Assessment of CA 15.3, CEA and TPA concentrations during monitoring of breast cancer.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2000;38(5):453-63.
1999: MK Tuxen; György Sölétormos; Per Hyltoft Petersen; V Schioler; Per Dombernowsky
Assessment of biological variation and analytical imprecision of CA 125, CEA, and TPA in relation to monitoring of ovarian cancer.
Gynecologic oncology 1999;74(1):12-22.
1997: György Sölétormos; J M Fogh; B Sehested-Hansen; Mogens Spang-Thomsen; V Schiøler; Per Dombernowsky; Torben Skovsgaard
Carcino-embryonic antigen in monitoring the growth of human colon adenocarcinoma tumour cells SK-CO-1 and HT-29 in vitro and in nude mice.
European journal of cancer (Oxford, England : 1990) 1997;33(1):108-14.
1996: György Sölétormos; D Nielsen; V Schiøler; Torben Skovsgaard; Per Dombernowsky
Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-up.
Clinical chemistry 1996;42(4):564-75.
1995: MK Tuxen; György Sölétormos; Per Dombernowsky
Tumor markers in the management of patients with ovarian cancer.
Cancer treatment reviews 1995;21(3):215-45.
1993: György Sölétormos; D Nielsen; V Schiøler; Torben Skovsgaard; P Winkel; H T Mouridsen; Per Dombernowsky
A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPA.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(10):861-9.
1993: F Bach; B Bjerregaard; György Sölétormos; F W Bach; Thomas Horn
Diagnostic value of cerebrospinal fluid cytology in comparison with tumor marker activity in central nervous system metastases secondary to breast cancer.
Cancer 1993;72(8):2376-82.
1993: György Sölétormos; V Schiøler; D Nielsen; Torben Skovsgaard; Per Dombernowsky
Interpretation of results for tumor markers on the basis of analytical imprecision and biological variation.
Clinical chemistry 1993;39(10):2077-83.
1993: Claus K Høgdall; György Sölétormos; D Nielsen; Bent Nørgaard-Pedersen; Per Dombernowsky; I Clemmensen
Prognostic value of serum tetranectin in patients with metastatic breast cancer.
Acta oncologica (Stockholm, Sweden) 1993;32(6):631-6.
1992: György Sölétormos; D Nielsen; V Schiøler; Torben Skovsgaard; Per Dombernowsky
Carbohydrate antigen 549 in metastatic breast cancer during cytostatic treatment and follow-up.
European journal of cancer (Oxford, England : 1990) 1992;28A(4-5):845-50.